Search results
Results from the WOW.Com Content Network
MRI of the breasts has the highest sensitivity to detect breast cancer when compared with other imaging modalities such as breast ultrasound or mammography. In the screening for breast cancer for high-risk women, sensitivity of MRI ranges from 83 to 94% while specificity (the confidence that a lesion is cancerous and not a false positive ...
As a free solubilized aqueous ion, gadolinium(III) is highly toxic, but the chelated compounds are generally regarded as safe for individuals without kidney disease. Free Gd 3+ has a median lethal dose of 0.34 mmol/kg (IV, mouse) [ 27 ] or 100–200 mg/kg, but the LD50 is increased by a factor of 31 times [ 28 ] when Gd 3+ is chelated.
Breast ultrasound is another technology employed in diagnosis and screening that can help differentiate between fluid filled and solid lesions, an important factor to determine if a lesion may be cancerous. [2] Breast MRI is a technology typically reserved for high-risk patients and patients recently diagnosed with breast cancer. [3]
An early clinical trial examines MRI guided ablation to destroy early stage breast cancer tumors. People still need to undergo chemotherapy, radiation. Mom receives new procedure to remove breast ...
Gadoteric acid, sold under the brand name Dotarem among others, is a macrocycle-structured gadolinium-based MRI contrast agent (GBCA).It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd 3+), and is used in form of the meglumine salt (gadoterate meglumine).
MRI without contrast agents is the imaging mode of choice for pre-surgical, in-utero diagnosis and evaluation of fetal tumors, primarily teratomas, facilitating open fetal surgery, other fetal interventions, and planning for procedures (such as the EXIT procedure) to safely deliver and treat babies whose defects would otherwise be fatal.
For women at high risk, NCCN recommends undergoing an annual mammogram and breast MRI between the ages of 25 and 40, considering the specific gene mutation type or the youngest age of breast cancer occurrence in the family. Additionally, NCCN suggests that high-risk women undergo clinical breast exams every 6 to 12 months starting at age 25.
Breast density is assessed by mammography and expressed as a percentage of the mammogram occupied by radiologically dense tissue (percent mammographic density or PMD). [23] About half of middle-aged women have dense breasts, and breasts generally become less dense as they age. Higher breast density is an independent risk factor for breast cancer.